ArticleTheranostics2021
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 31 citations in OpenAlex.
- Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.Non-coding RNA · 2026Article
- Bioengineered miR-148a-3p suppresses glycolysis and amino acid homeostasis in hepatocellular carcinoma cells by regulating multiple solute carrier transporters.Liver research (Beijing, China) · 2026Article
- Design, expression, purification, and application of novel recombinant miR-491 molecules to define the biogenesis and function of miR-491-3p versus -5p in posttranscriptional regulation of UDP-glucuronosyltransferase 1A1.Drug metabolism and disposition: the biological fate of chemicals · 2026Article
- Comparative effectiveness of 7 major human let-7-5p isoforms to modulate target gene expression in liver cells.Drug metabolism and disposition: the biological fate of chemicals · 2026Article
- Efficiency and safety of five different agents forFrontiers in molecular biosciences · 2026Article
- A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control.Communications biology · 2025Article
- In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.International journal of molecular sciences · 2025Article
- In Vivo Fermentation Production of RNA Interference Agents.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Bioengineered miR-7-5p modulates non-small cell lung cancer cell metabolism to improve therapy.Molecular pharmacology · 2025Article
- Comparison of Three Computational Tools for the Prediction of RNA Tertiary Structures.Non-coding RNA · 2024Article
- The Precise Basecalling of Short-Read Nanopore Sequencing.bioRxiv : the preprint server for biology · 2024Article
- Molecular Engineering of Functional SiRNA Agents.ACS synthetic biology · 2024Article
- Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents.RNA (New York, N.Y.) · 2024Article
- Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.Nature communications · 2024Article
- Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs.Frontiers in pharmacology · 2024Review
- Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.Acta pharmaceutica Sinica. B · 2023Article
- A novel recombinant ORF7-siRNA delivered by flexible nano-liposomes inhibits varicella zoster virus infection.Cell & bioscience · 2023Article
- Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
- Microtubule actin crosslinking factor 1 functions as a novel therapeutic target in lung metastasis of osteosarcoma.Genes & diseases · 2023Article
- The miR-124-3p regulates the allergic airway inflammation and remodeling in an ovalbumin-asthmatic mouse model by inhibiting S100A4.Immunity, inflammation and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Peng-Cheng LiDepartment of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
Mei-Juan TuDepartment of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Pui Yan HoDepartment of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Neelu BatraDepartment of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Michelle M L TranDepartment of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Jing-Xin QiuDepartment of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Theodore WunDivision of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Primo N LaraDepartment of Internal Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Xiang HuDepartment of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
Ai-Xi YuDepartment of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
Ai-Ming YuDepartment of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
University of California, Davis · USRoswell Park Comprehensive Cancer Center · US
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9MNovel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7MSupplement: Recombinant microRNAs in xenobiotic metabolism and dispositionR35GM140835 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2021 to 2025
$2.0MRecombinant microRNAs in xenobiotic and nutrient dispositionR01CA253230 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Meijuan Tu · 2021 to 2026
$1.7MRecombinant microRNAs in xenobiotic dispositionR01GM113888 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2016 to 2019
$1.3MNCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225958NCI NIH HHS R01 CA253230NIGMS NIH HHS R01 GM113888NIGMS NIH HHS R35 GM140835
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBioengineeringCell Line, TumorCell ProliferationFermentationGene ExpressionGenetic TherapyHumansLung NeoplasmsMiceMicroRNAsMolecular Targeted TherapyNeoplasmsNeoplasm TransplantationOsteosarcomaRNAMicroRNAsMIRN124 microRNA, humanMIRN34 microRNA, humanRNARNA, recombinantRNA, TransferbioengineeringcancermiRNAncRNAtherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.